Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Benvenue Medical
company
About
Benvenue Medical is a biotech company developing innovative and minimally invasive surgical solutions for the treatment of spinal disorders.
- 101 - 250
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $35.50M
- Industries
- Biotechnology,Health Care,Medical,Medical Device
- Founded date
- Jan 1, 2004
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Benvenue Medical, Inc. is developing innovative, minimally invasive surgical solutions to treat spinal disorders. The company is privately held and funded by CRG Partners.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
5
$138.50M
Benvenue Medical has raised a total of
$138.50M
in funding over 2 rounds. Their latest funding was raised on
Jan 7, 2016 from a Series F round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 7, 2016 | Series F | $23M | 1 |
Versant Ventures
|
— | Detail |
| Jun 18, 2014 | Series E | $40M | 1 | — | — | Detail |
| Jun 28, 2012 | Series D | $25M | 1 | — | — | Detail |
| Apr 18, 2011 | Series C | $35.50M | 1 | — | — | Detail |
| Jan 7, 2008 | Series B | $15M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Benvenue Medical is funded by 1 investors.
Versant Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Versant Ventures
|
Yes | Series F |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
